About Evommune, Inc. (EVMN)
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
EVMN Key Statistics
| Current Price | $26.50 | Market Cap | $862 million |
|---|---|---|---|
| Daily Change | +5.62% | Volume | 173K |
| 52-Week High | $33.20 | 52-Week Low | $13.89 |
| Sector | Healthcare | Industry | Biotechnology |
EVMN Price Performance
Evommune, Inc. stock has returned +8.09% over the past day, +4.31% over the past week, -14.10% over the past month, and +27.62% over the past three months. The stock trades between a 52-week low of $13.89 and a high of $33.20.
EVMN Financial Fundamentals
Evommune, Inc. reports a return on equity (ROE) of -224.59%, operating margin of -623.62%. The debt-to-equity ratio is 0.01. Current ratio stands at 8.57.